Azenta, Inc. (NASDAQ:AZTA) Given Average Recommendation of “Hold” by Brokerages

Shares of Azenta, Inc. (NASDAQ:AZTA) have received a consensus recommendation of “Hold” from the eight research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $41.3333.

Several equities analysts have recently weighed in on AZTA shares. Needham & Company LLC reiterated a “buy” rating and set a $44.00 price objective on shares of Azenta in a report on Tuesday, March 17th. Evercore cut their price objective on Azenta from $50.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Zacks Research upgraded Azenta from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. Wall Street Zen cut Azenta from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, Jefferies Financial Group cut their target price on Azenta from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, February 4th.

Azenta Price Performance

NASDAQ:AZTA opened at $26.40 on Tuesday. Azenta has a fifty-two week low of $19.87 and a fifty-two week high of $41.73. The stock has a market capitalization of $1.22 billion, a PE ratio of -19.56 and a beta of 1.47. The business’s 50-day simple moving average is $24.31 and its 200-day simple moving average is $30.63.

Azenta (NASDAQ:AZTA) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). Azenta had a negative net margin of 10.34% and a positive return on equity of 1.43%. The business had revenue of $148.64 million for the quarter, compared to the consensus estimate of $146.89 million. During the same quarter last year, the firm earned $0.08 EPS. The company’s revenue for the quarter was up .8% on a year-over-year basis. On average, research analysts expect that Azenta will post 0.71 earnings per share for the current year.

Institutional Investors Weigh In On Azenta

Institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd raised its stake in shares of Azenta by 2,067.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock worth $27,000 after purchasing an additional 765 shares in the last quarter. Assetmark Inc. raised its stake in shares of Azenta by 54.1% during the 4th quarter. Assetmark Inc. now owns 832 shares of the company’s stock worth $28,000 after purchasing an additional 292 shares in the last quarter. Bessemer Group Inc. increased its holdings in shares of Azenta by 249.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,017 shares of the company’s stock worth $29,000 after acquiring an additional 726 shares during the last quarter. Osaic Holdings Inc. increased its holdings in shares of Azenta by 44.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after acquiring an additional 385 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of Azenta by 98.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock worth $46,000 after acquiring an additional 689 shares during the last quarter. Institutional investors own 99.08% of the company’s stock.

Azenta Company Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end?to?end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next?generation sequencing (NGS), DNA synthesis, and molecular biology services.